A maker of employer-sponsored fertility and women's health benefits, Progyny bundles treatment into "Smart Cycles" supported by its Progyny Rx pharmacy and a national network of fertility specialists, serving large self-insured employers and their families. Founded in New York in 2008 as a medical-device startup (Auxogen Bioscience) that built an embryo-testing tool, it pivoted to benefits in 2015 and adopted its name—a playful twist on "progeny" (meaning offspring)—to reflect its mission of helping people build families. Progyny has since expanded into pregnancy, postpartum, menopause, and family-wellbeing support.
Progyny's Q2 gross margin reached 25.5%, its highest in over five years, as a sharp drop in stock-based compensation amplified operating leverage.
Progyny's rose 64% even as growth remained in the single digits. Revenue increased 5% to $350.5 million and expanded 1.8 points to 25.5%, driven by care management efficiencies and a $3.4 million decline in within cost of services. The company is now extracting more profit from each dollar of revenue, but the margin gains are partly tied to a non-cash expense that is normalizing.
Key takeaways
rose 64.2% to $40.0 million, far outpacing the 5.3% increase, because total operating expenses fell 10% as declined across all functions.
expanded 1.8 percentage points to 25.5%, the highest level in the dataset, driven by ongoing care management efficiencies and a $3.4 million decrease in within cost of services.
grew 5.3% to $350.5 million, with the fertility benefits solution contributing a $16.3 million increase from more clients and covered lives, while the pharmacy solution, Progyny Rx, grew more slowly.
Section summaries
Management's Discussion and Analysis
Revenue grew 5% YoY to $350.5M in Q2 FY2026, with gross margin expanding 180 bps to 25.5% driven by care management efficiencies and lower stock-based compensation.
⌄
Total increased 5% to $350.5 million, primarily from a $16.3 million rise in fertility benefits solution revenue due to more clients and covered lives.
expanded 180 to 25.5%, driven by ongoing care management efficiencies and a $3.4 million decrease in within cost of services.
rose 63.9% to $28.1 million, while increased 7% to $62.1 million, a divergence that reflects lower interest income and higher .
The company repurchased $148.1 million of common stock during the first half of 2026 and had $168.5 million remaining under its authorization, with $152.6 million in cash and equivalents and an undrawn $200 million .
What changed
The Q1 2026 watch item on sustainability is partially answered: the 25.3% margin from Q1 expanded further to 25.5% in Q2, confirming the step-up was not a one-quarter event, though the filing attributes the gain partly to a $3.4 million decline that may not repeat.
growth re-accelerated to 5.3% from 1.4% in Q1 2026, as the drag from a lost client's transition services that had suppressed the Q1 comparison began to fade, though the rate remains below the 9.5% posted in Q2 2025.
The company exhausted its $200 million program in Q1 2026 and deployed another $148.1 million in the first half under a new authorization, a pace of buybacks that continues to reduce the share count and support growth even as growth moderates.
The remained elevated, with growth of 63.9% trailing growth of 64.2%, confirming that the lower tax benefits from equity compensation activity flagged in FY2025 have persisted into FY2026.
What to watch
Whether can hold above 25% once normalizes, or if the 25.5% Q2 level represents a peak driven by a non-recurring $3.4 million decline in that expense line.
The pace of client and covered-life additions in Q3 2026, to assess whether growth can continue re-accelerating from the 5.3% Q2 rate toward the double-digit rates of prior years now that the lost client's transition services have fully lapped.
Whether the company continues to draw on its authorization at the current pace, and how that affects the $152.6 million cash balance and the undrawn $200 million .
The trajectory of interest income and expense in Q3, to confirm whether the gap between growth and growth narrows or persists as a new run-rate.
Total operating expenses fell 10% to $49.3 million, largely due to a $12.4 million reduction in expense across all functions.
rose 64% to $28.1 million, while increased 7% to $62.1 million.
The company repurchased $148.1 million of common stock during the first half of 2026 under its programs, with $168.5 million remaining authorized.
Cash provided by operating activities was $96.4 million for the six months ended June 30, 2026, and the company held $152.6 million in cash and equivalents with no amounts drawn on its $200 million .
Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in…
⌄
We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily the result of fluctuations in interest rates.
Interest Rate Risk
Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors and other factors beyond our control.
At June 30, 2026, we had cash and cash equivalents of $152.6 million and marketable securities of $84.3 million. Interest-earning instruments carry a degree of interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure. Our investments are exposed to market risk due to a fluctuation in interest rates, which may affect our interest income and the fair market value of our investments. A hypothetical 1% change in interest rates would not result in a material impact on our consolidated financial statements.
Inflation Rate Risk
While it is difficult to accurately measure the impact of inflation on our results of operations and financial condition, we do not believe that inflation has had a material effect on our business, financial condition or results of operations. Nonetheless, if our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases. Our inability or failure to do so could harm our business, financial condition, and results of operations.
41
Table of contents
Key risks include failing to meet guidance, intense competition, client concentration in tech, utilization unpredictability, and evolving healthcare regulation.
⌄
Failure to meet publicly issued or analyst expectations could cause a significant stock price decline.
Intense competition from more established insurers and new entrants, including fertility-focused PBMs, may erode market share and pricing power.
A significant portion of comes from the technology industry, making the business vulnerable to downturns or consolidation in that sector.
Unpredictable member rates or treatment mix could cause client costs to exceed budgets, threatening client retention and profitability.
Evolving federal and state reforms, including new rebate pass-through and disclosure laws, may materially impact the Progyny Rx business model.
The company's expansion into new offerings (e.g., menopause, parental leave) and reliance on AI introduces operational, regulatory, and reputational risks.